Psyence Biomedical (PBM) Enterprise Value (2023 - 2026)

Psyence Biomedical's Enterprise Value history runs 4 years deep, the most recent figure standing at -$7.4 million for Q1 2026.

• On a quarterly basis, Enterprise Value fell 20.64% year-over-year to -$7.4 million in Q1 2026; TTM through Mar 2026 was -$7.4 million, a 20.64% decrease from a year earlier, with the FY2026 full-year figure at -$7.4 million, down 20.64% from the prior year.
• Enterprise Value fell to -$7.4 million in Q1 2026 per PBM's latest filing, from -$7.2 million in the prior quarter.
• Across five years, Enterprise Value topped out at -$0.09 in Q3 2023 and bottomed at -$7.4 million in Q1 2026.
• The 4-year median for Enterprise Value is -$2.0 million (2024), against an average of -$3.6 million.
• Biggest YoY gain for Enterprise Value was 44.07% in 2024; the steepest drop was 2225293070.32% in 2024.
• Year by year, Enterprise Value stood at -$0.09 in 2023, then tumbled by 2225293070.32% to -$2.0 million in 2024, then plunged by 266.8% to -$7.2 million in 2025, then retreated by 3.44% to -$7.4 million in 2026.
• Per Business Quant, the three latest PBM Enterprise Value figures stand at -$7.4 million (Q1 2026), -$7.2 million (Q3 2025), and -$6.2 million (Q1 2025).